ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
alectinib Sensitive: A1 - Approval
Future Oncol - 2 days (New A1)
|
alectinib Sensitive: A1 - Approval
Future Oncol - 2 days - (New C3)
|
FAT1 mutation
|
NSCLC
|
FAT1 mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
NPJ Precis Oncol - 2 days (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
NPJ Precis Oncol - 2 days - (New C3)
|
Chr del(9)(p21.3)
|
Lung Non-Squamous Non-Small Cell Cancer
|
Chr del(9)(p21.3)
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Resistant: C3 – Early Trials
NPJ Precis Oncol - 2 days (New C3)
|
Immunotherapy Resistant: C3 – Early Trials
NPJ Precis Oncol - 2 days - (New C3)
|
MET amplification + MET exon 14 mutation + EGFR exon 20 insertion
|
LUAD
|
MET amplification + MET exon 14 mutation + EGFR exon 20 insertion
|
LUAD
|
crizotinib Sensitive: C4 – Case Studies
BMC Med Genomics - 2 days (New C4)
|
crizotinib Sensitive: C4 – Case Studies
BMC Med Genomics - 2 days - (New C4)
|
NF2 deletion
|
Malignant Pleural Mesothelioma
|
NF2 deletion
|
Malignant Pleural Mesothelioma
|
IK-930 Sensitive: B - Late Trials
Ikena Oncology Press Release - 3 days (New B)
|
IK-930 Sensitive: B - Late Trials
Ikena Oncology Press Release - 3 days - (New B)
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
capmatinib Sensitive: A1 - Approval
Novartis Press Release - 3 days (New A1)
|
capmatinib Sensitive: A1 - Approval
Novartis Press Release - 3 days - (New A1)
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
osimertinib Sensitive: C2 – Inclusion Criteria
Lung Cancer - 3 days (New C2)
|
osimertinib Sensitive: C2 – Inclusion Criteria
Lung Cancer - 3 days - (New C3)
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
Lung Cancer - 5 days (New B)
|
Immunotherapy Sensitive: B - Late Trials
Lung Cancer - 5 days - (New C3)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
pemetrexed Sensitive: C2 – Inclusion Criteria
Int J Clin Oncol - 5 days (New C2)
|
pemetrexed Sensitive: C2 – Inclusion Criteria
Int J Clin Oncol - 5 days - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Lung Cancer - 5 days (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days (New C3)
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
|
KEAP1 mutation
|
NSCLC
|
KEAP1 mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days (New C3)
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
|
STK11 mutation + KEAP1 mutation + KRAS G12C
|
NSCLC
|
STK11 mutation + KEAP1 mutation + KRAS G12C
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Lung Cancer - 5 days (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
|
KDR expression
|
NSCLC
|
KDR expression
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Cancer Sci - 5 days (New C3)
|
Immunotherapy Resistant: C3 – Early Trials
Cancer Sci - 5 days - (New C3)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
osimertinib Sensitive: A2 - Guideline
Future Oncol - 1 week (New A2)
|
osimertinib Sensitive: A2 - Guideline
Future Oncol - 1 week - (New C3)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
BMC Cancer - 1 week (New A1)
|
osimertinib Sensitive: A1 - Approval
BMC Cancer - 1 week - (New C3)
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
Onco Targets Ther - 1 week (New A1)
|
osimertinib Sensitive: A1 - Approval
Onco Targets Ther - 1 week - (New C4)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
Front Pharmacol - 1 week (New A1)
|
dacomitinib Sensitive: A1 - Approval
Front Pharmacol - 1 week - (New C3)
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
Onco Targets Ther - 1 week (New A1)
|
erlotinib Sensitive: A1 - Approval
Onco Targets Ther - 1 week - (New C4)
|
EGFR exon 19 deletion + PD-L1 expression
|
NSCLC
|
EGFR exon 19 deletion + PD-L1 expression
|
NSCLC
|
osimertinib Sensitive: C3 – Early Trials
Sci Rep - 1 week (New C3)
|
osimertinib Sensitive: C3 – Early Trials
Sci Rep - 1 week - (New C3)
|
FOXM1 rs3742076_G
|
NSCLC
|
FOXM1 rs3742076_G
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
Clin Cancer Res - 1 week (New C3)
|
gefitinib Resistant: C3 – Early Trials
Clin Cancer Res - 1 week - (New C3)
|
EML4-ALK variant 2
|
LUAD
|
EML4-ALK variant 2
|
LUAD
|
ALK inhibitor Sensitive: C4 – Case Studies
Springer - 1 week (New C4)
|
ALK inhibitor Sensitive: C4 – Case Studies
Springer - 1 week - (New C4)
|
CFTR expression
|
LUAD
|
CFTR expression
|
LUAD
|
CFTR potentiator Sensitive: D – Preclinical
J Cancer Res Clin Oncol - 1 week (New D)
|
CFTR potentiator Sensitive: D – Preclinical
J Cancer Res Clin Oncol - 1 week - (New D)
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 2 weeks (New A1)
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 2 weeks - (New A1)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR inhibitor Sensitive: B - Late Trials
Cancer Med - 2 weeks (New B)
|
EGFR inhibitor Sensitive: B - Late Trials
Cancer Med - 2 weeks - (New C3)
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TPX-0005 Sensitive: B - Late Trials
Zai Lab Press Release - 2 weeks (New B)
|
TPX-0005 Sensitive: B - Late Trials
Zai Lab Press Release - 2 weeks - (New C3)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
afatinib Sensitive: A1 - Approval
Thorac Cancer - 2 weeks (New A1)
|
afatinib Sensitive: A1 - Approval
Thorac Cancer - 2 weeks - (New C3)
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
afatinib Sensitive: A1 - Approval
Thorac Cancer - 2 weeks (New A1)
|
afatinib Sensitive: A1 - Approval
Thorac Cancer - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
Roche Press Release - 2 weeks (New A1)
|
atezolizumab Sensitive: A1 - Approval
Roche Press Release - 2 weeks - (New A1)
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
Oncology - 2 weeks (New A2)
|
crizotinib Sensitive: A2 - Guideline
Oncology - 2 weeks - (New C3)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
afatinib Sensitive: B - Late Trials
Thorac Cancer - 2 weeks (New B)
|
afatinib Sensitive: B - Late Trials
Thorac Cancer - 2 weeks - (New C3)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
MRTX849 Sensitive: B - Late Trials
Cancer Discov - 2 weeks (New B)
|
MRTX849 Sensitive: B - Late Trials
Cancer Discov - 2 weeks - (New C3)
|
KDM5C mutation
|
NSCLC
|
KDM5C mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
afatinib Sensitive: C3 – Early Trials
Clin Transl Oncol - 2 weeks (New C3)
|
afatinib Sensitive: C3 – Early Trials
Clin Transl Oncol - 2 weeks - (New D)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
PD1 inhibitor Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks (New C3)
|
PD1 inhibitor Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
|
KMT2C mutation
|
NSCLC
|
KMT2C mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks (New C3)
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
|
KRAS mutation
|
NSCLC
|
KRAS mutation
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
durvalumab Sensitive: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Sensitive: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
KMT2C mutation + BCOR mutation + KDM5C mutation
|
NSCLC
|
KMT2C mutation + BCOR mutation + KDM5C mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
BCOR mutation
|
NSCLC
|
BCOR mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab + SNK01 Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks (New C3)
|
pembrolizumab + SNK01 Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
|
NTRK2 fusion
|
NSCLC
|
NTRK2 fusion
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
EML4-ALK fusion
|
NSCLC
|
EML4-ALK fusion
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
HER-2 exon 20 insertion
|
NSCLC
|
HER-2 exon 20 insertion
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks (New C3)
|
durvalumab Resistant: C3 – Early Trials
JAMA Netw Open - 2 weeks - (New C3)
|
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H
|
NSCLC
|
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression
|
NSCLC
|
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks (New C3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancers (Basel) - 2 weeks - (New C3)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
osimertinib Sensitive: C4 – Case Studies
Clin Transl Oncol - 2 weeks (New C4)
|
osimertinib Sensitive: C4 – Case Studies
Clin Transl Oncol - 2 weeks - (New D)
|
FGFR2-ERC1 fusion
|
LUAD
|
FGFR2-ERC1 fusion
|
LUAD
|
anlotinib Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks (New C4)
|
anlotinib Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks - (New C4)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
erlotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
erlotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
erlotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
erlotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
afatinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
afatinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
osimertinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
osimertinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
dacomitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
dacomitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
icotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
icotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
EGFR exon 19 deletion + EGFR L861Q
|
LUAD
|
gefitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
gefitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
gefitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
gefitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
icotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
icotinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR L861Q
|
LUAD
|
EGFR L861Q
|
LUAD
|
dacomitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks (New D)
|
dacomitinib Sensitive: D – Preclinical
Clin Transl Oncol - 2 weeks - (New D)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
BMC Cancer - 3 weeks (New A1)
|
osimertinib Sensitive: A1 - Approval
BMC Cancer - 3 weeks - (New C3)
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
afatinib Resistant: A2 - Guideline
Target Oncol - 3 weeks (New A2)
|
afatinib Resistant: A2 - Guideline
Target Oncol - 3 weeks - (New C4)
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
furmonertinib Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks (New B)
|
furmonertinib Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks - (New B)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
furmonertinib Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks (New B)
|
furmonertinib Sensitive: B - Late Trials
Lancet Respir Med - 3 weeks - (New B)
|
NTRK2 fusion
|
Lung Cancer
|
NTRK2 fusion
|
Lung Cancer
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks (New C1)
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
|
NTRK1 fusion
|
Lung Cancer
|
NTRK1 fusion
|
Lung Cancer
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks (New C1)
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
|
NTRK3 fusion
|
Lung Cancer
|
NTRK3 fusion
|
Lung Cancer
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks (New C1)
|
larotrectinib Sensitive: C1 - Off-label
J Clin Oncol - 3 weeks - (New C3)
|
EGFR T790M
|
Lung Cancer
|
EGFR T790M
|
Lung Cancer
|
osimertinib Sensitive: C1 - Off-label
Transl Oncol - 3 weeks (New C1)
|
osimertinib Sensitive: C1 - Off-label
Transl Oncol - 3 weeks - (New D)
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Cancer Manag Res - 3 weeks (New C2)
|
bevacizumab Sensitive: C2 – Inclusion Criteria
Cancer Manag Res - 3 weeks - (New C3)
|
MET negative + EGFR mutation
|
NSCLC
|
MET negative + EGFR mutation
|
NSCLC
|
osimertinib + selumetinib Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks (New C3)
|
osimertinib + selumetinib Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks - (New C3)
|
ABCB6 expression
|
NSCLC
|
ABCB6 expression
|
NSCLC
|
gemcitabine Resistant: C3 – Early Trials
Cell Mol Life Sci - 3 weeks (New C3)
|
gemcitabine Resistant: C3 – Early Trials
Cell Mol Life Sci - 3 weeks - (New C3)
|
CD74-ROS1 fusion
|
Malignant Pleural Mesothelioma
|
CD74-ROS1 fusion
|
Malignant Pleural Mesothelioma
|
crizotinib Sensitive: C4 – Case Studies
J Cancer Res Clin Oncol - 3 weeks (New C4)
|
crizotinib Sensitive: C4 – Case Studies
J Cancer Res Clin Oncol - 3 weeks - (New C4)
|
EGFR exon 19 deletion + EGFR G724S
|
Lung Cancer
|
EGFR exon 19 deletion + EGFR G724S
|
Lung Cancer
|
dacomitinib Sensitive: C4 – Case Studies
Invest New Drugs - 3 weeks (New C4)
|
dacomitinib Sensitive: C4 – Case Studies
Invest New Drugs - 3 weeks - (New C4)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
lorlatinib Sensitive: A1 - Approval
|
lorlatinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib Sensitive: A1 - Approval
|
sotorasib Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
tepotinib Sensitive: A1 - Approval
|
tepotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
lazertinib Sensitive: A1 - Approval
|
lazertinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
mobocertinib Sensitive: A1 - Approval
|
mobocertinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
DP Sensitive: A1 - Approval
|
DP Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ensartinib Sensitive: A1 - Approval
|
ensartinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
savolitinib Sensitive: A1 - Approval
|
savolitinib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
topotecan Sensitive: A1 - Approval
|
topotecan Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
|
carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
LUAD
|
No biomarker
|
LUAD
|
nintedanib Sensitive: A1 - Approval
|
nintedanib Sensitive: A1 - Approval
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
EGFR expression
|
Lung Non-Small Cell Squamous Cancer
|
necitumumab Sensitive: A1 - Approval
|
necitumumab Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
lurbinectedin Sensitive: A1 - Approval
|
lurbinectedin Sensitive: A1 - Approval
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
amivantamab-vmjw Sensitive: A1 - Approval
|
amivantamab-vmjw Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
docetaxel Sensitive: A1 - Approval
|
docetaxel Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ceritinib Sensitive: A1 - Approval
|
ceritinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
aumolertinib Sensitive: A1 - Approval
|
aumolertinib Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: A1 - Approval
|
sintilimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
ALK mutation
|
NSCLC
|
ALK mutation
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
erlotinib + ramucirumab Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
BRAF V600
|
NSCLC
|
BRAF V600
|
NSCLC
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
No biomarker
|
Lung Non-Small Cell Squamous Cancer
|
sintilimab Sensitive: A1 - Approval
|
sintilimab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
EGFR mutation + ALK negative + TMB-H
|
NSCLC
|
EGFR mutation + ALK negative + TMB-H
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
BRAF V600E
|
NSCLC
|
BRAF V600E
|
NSCLC
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
ROS1 rearrangement
|
NSCLC
|
ROS1 rearrangement
|
NSCLC
|
ceritinib Sensitive: A2 - Guideline
|
ceritinib Sensitive: A2 - Guideline
|